HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at HC Wainwright lowered their FY2024 EPS estimates for 4D Molecular Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($2.89) for the year, down from their prior estimate of ($2.59). HC Wainwright currently has a "Buy" rating and a $36.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.81) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($3.23) EPS.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Thursday. Leerink Partners reaffirmed an "outperform" rating and issued a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $47.00.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.51 during mid-day trading on Monday, reaching $8.32. 1,909,091 shares of the company were exchanged, compared to its average volume of 897,701. 4D Molecular Therapeutics has a fifty-two week low of $7.32 and a fifty-two week high of $36.25. The company has a market capitalization of $384.63 million, a P/E ratio of -3.10 and a beta of 2.82. The business's 50 day simple moving average is $10.30 and its 200 day simple moving average is $17.03.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at $40,000. Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth about $57,000. China Universal Asset Management Co. Ltd. raised its holdings in 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after buying an additional 3,922 shares during the period. Proficio Capital Partners LLC acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth about $108,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company's stock valued at $110,000 after purchasing an additional 3,026 shares during the period. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.